Grail IPO
Grail was a biotechnology company focused on developing blood-based tests for early cancer detection using circulating tumor DNA. The company developed the Galleri test, a multi-cancer early detection screening test that can identify over 50 types of cancer from a single blood draw.
What We Know
Grail was acquired by Illumina in 2021 for approximately $7.1 billion, though the acquisition faced significant regulatory challenges. The company had previously been spun out from Illumina in 2016 and had raised substantial private funding, achieving a valuation of over $3 billion before the acquisition. The acquisition was controversial and faced antitrust scrutiny from regulators in both the US and Europe, who were concerned about vertical integration in the genomics market. As a result of regulatory pressure, Illumina was required to divest Grail, and the company was spun out again as an independent entity in 2024.
Frequently Asked Questions
Has Grail had an IPO?
Grail has not had a traditional IPO. The company was acquired by Illumina in 2021 but was later spun out again due to regulatory requirements.
When is the Grail IPO date?
There is currently no confirmed IPO date for Grail following its recent spin-out from Illumina. Sign up for alerts to stay informed.
How can I buy Grail stock?
Grail stock is not currently available for purchase on public markets following its complex ownership changes. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts